Metabolic syndrome and carotid intima-media thickness in young adults: Roles of apolipoprotein B, apolipoprotein A-I, C-reactive protein, and secretory phospholipase A2: The cardiovascular risk in young finns study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 9, 2010, Pages 1861-1866

  Mattsson, Noora ^a   Magnussen, Costan G ^a   Rönnemaa, Tapani ^b   Mallat, Ziad ^f,g   Benessiano, Joelle ^f   Jula, Antti ^c   Taittonen, Leena ^d   Kähönen, Mika ^e   Juonala, Markus ^a,b   Viikari, Jorma ^b   Raitakari, Olli T ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d VAASA CENTRAL HOSPITAL   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f INSERM   (France)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

apolipoproteins; C reactive protein; carotid intima media thickness; metabolic syndrome; type II secretory phospholipase A2

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; SECRETORY PHOSPHOLIPASE A2; APOA1 PROTEIN, HUMAN; AUTACOID; BIOLOGICAL MARKER;

ADULT; ARTERIAL WALL THICKNESS; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ARTERY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME ACTIVITY; HUMAN; INCIDENCE; INFLAMMATION; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROSPECTIVE STUDY; AGE; BLOOD; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; COMPLICATION; CROSS-SECTIONAL STUDY; ECHOGRAPHY; FEMALE; FINLAND; INTIMA; MALE; METABOLISM; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; TUNICA MEDIA; YOUNG ADULT;

ADULT; AGE FACTORS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; FINLAND; HUMANS; INCIDENCE; INFLAMMATION MEDIATORS; LINEAR MODELS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; PHOSPHOLIPASES A2, SECRETORY; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUNICA INTIMA; TUNICA MEDIA; YOUNG ADULT;

EID: 77955980286     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.204669     Document Type: Article

References (36)

1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288: 2709-2716.
2. Williams K, Sniderman AD, Sattar N, D'Agostino R, Jr, Wagenknecht LE, Haffner SM. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the insulin resistance atherosclerosis study (IRAS). Circulation. 2003; 108:2312-2316.
3. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-2033.
4. Lind L, Vessby B, Sundstrom J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol. 2006;26:406-410.
5. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. Circulation. 1999;99:237-242.
6. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347: 1557-1565.
7. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. Circulation. 2003;108:414-419.
8. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391-397.
9. Szmitko PE, Wang CH, Weisel RD, De Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: part I. Circulation. 2003;108:1917-1923.
10. Conen D, Rexrode KM, Creager MA, Ridker PM, Pradhan AD. Metabolic syndrome, inflammation, and risk of symptomatic peripheral artery disease in women: a prospective study. Circulation. 2009;120: 1041-1047.
11. Kivimäki M, Lawlor DA, Eklund C, Smith GD, Hurme M, Lehtimäki T, Viikari JS, Raitakari OT. Mendelian randomization suggests no causal association between C-reactive protein and carotid intima-media thickness in the young Finns study. Arterioscler Thromb Vasc Biol. 2007;27:978-979.
12. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nor-destgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897-1908.
13. Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P. Phospholipase A(2) in vascular disease. Circ Res. 2001;89:298-304.
14. Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arguelles C, Cohen A, Huart V, Wareham NJ, Luben R, Khaw KT, Tedgui A, Boekholdt SM. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol. 2007;27:1177-1183.
15. Rosenson RS. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther. 2009;23:93-101.
16. Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, Sandhu MS, Jukema JW, Kastelein JJ, Hack CE, Khaw KT. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2005;25: 839-846.
17. Mattsson N, Rönnemaa T, Juonala M, Viikari JS, Jokinen E, Hutri-Kähönen N, Kähönen M, Laitinen T, Raitakari OT. Arterial structure and function in young adults with the metabolic syndrome: the cardiovascular risk in young Finns study. Eur Heart J. 2008;29:784-791.
18. Koskinen J, Magnussen CG, Taittonen L, Räsänen L, Mikkilä V, Laitinen T, Rönnemaa T, Kähönen M, Viikari JS, Raitakari OT, Juonala M. Arterial structure and function after recovery from the metabolic syndrome: the cardiovascular risk in young Finns study. Circulation. 2010; 121:392-400.
19. Raitakari OT, Juonala M, Rönnemaa T, Keltikangas-Järvinen L, Räsänen L, Pietikäinen M, Hutri-Kähönen N, Taittonen L, Jokinen E, Marniemi J, Jula A, Telama R, Kähönen M, Lehtimäki T, Åkerblom HK, Viikari JS. Cohort profile: the cardiovascular risk in young Finns study. Int J Epidemiol. 2008;37:1220-1226.
20. Juonala M, Viikari JS, Hutri-Kähönen N, Pietikäinen M, Jokinen E, Taittonen L, Marniemi J, Rönnemaa T, Raitakari OT. The 21-year follow-up of the cardiovascular risk in young Finns study: risk factor levels, secular trends and east-west difference. J Intern Med. 2004;255: 457-468.
21. Juonala M, Viikari JS, Rönnemaa T, Taittonen L, Marniemi J, Raitakari OT. Childhood C-reactive protein in predicting CRP and carotid intima-media thickness in adulthood: the cardiovascular risk in young Finns study. Arterioscler Thromb Vasc Biol. 2006;26:1883-1888.
22. Mallat Z, Steg PG, Benessiano J, Tanguy ML, Fox KA, Collet JP, Dabbous OH, Henry P, Carruthers KF, Dauphin A, Arguelles CS, Masliah J, Hugel B, Montalescot G, Freyssinet JM, Asselain B, Tedgui A. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol. 2005;46:1249-1257.
23. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome\a new worldwide definition. Lancet. 2005;366:1059-1062.
24. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735-2752.
25. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European group for the study of insulin resistance (EGIR). Diabet Med. 1999;16:442-443.
26. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC, Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120: 1640-1645.
27. Raitakari OT, Juonala M, Kähönen M, Taittonen L, Laitinen T, Mäki-Torkko N, Järvisalo MJ, Uhari M, Jokinen E, Rönnemaa T, Åkerblom HK, Viikari JS. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the cardiovascular risk in young Finns study. JAMA. 2003;290:2277-2283.
28. Juonala M, Viikari JS, Kahonen M, Solakivi T, Helenius H, Jula A, Marniemi J, Taittonen L, Laitinen T, Nikkari T, Raitakari OT. Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study. J Am Coll Cardiol. 2008;52:293-299.
29. Festa A, D'Agostino R, Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 2000;102:42-47.
30. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
31. Leinonen E, Hurt-Camejo E, Wiklund O, Hulten LM, Hiukka A, Taskinen MR. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis. 2003;166:387-394.
32. Leinonen ES, Hiukka A, Hurt-Camejo E, Wiklund O, Sarna SS, Mattson HL, Westerbacka J, Salonen RM, Salonen JT, Taskinen MR. Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes. J Intern Med. 2004;256:119-127.
33. Tietge UJ, Maugeais C, Cain W, Grass D, Glick JM, De Beer FC, Rader DJ. Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cho-lesteryl ester and apolipoprotein A-I. J Biol Chem. 2000;275: 10077-10084.
34. Hakala JK, Öörni K, Pentikäinen MO, Hurt-Camejo E, Kovanen PT. Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol. 2001;21:1053-1058.
35. Järvisalo MJ, Harmoinen A, Hakanen M, Paakkunainen U, Viikari J, Hartiala J, Lehtimäki T, Simell O, Raitakari OT. Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler Thromb Vasc Biol. 2002;22:1323-1328.
36. Finn AV, Kolodgie FD, Virmani R. Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. Arterioscler Thromb Vasc Biol. 2010;30:177-181.